Market research
GLPG Galapagos NV ADR
NASDAQ USD Healthcare
Latest close
As of 07 Jun 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- 3.18
- Analyst target
- 27.5243
- Dividend yield
- Not available
- Beta
- 0.12
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 2B
- P/E ratio
- 3.18
- Analyst target
- 27.5243
- Dividend yield
- Not available
- Beta
- 0.12
About
About Galapagos NV ADR
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Research context
Galapagos NV ADR appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the GLPG discussion.
5 years, 7 months ago
Galapagos NV is currently in a long term downtrend where the price is trading 30.9% below its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.2.
Galapagos NV's total revenue rose by 21.1% to $144M since the same quarter in the previous year.
Its net income has increased by 49.9% to $-58M since the same quarter in the previous year.
Finally, its free cash flow grew by 42.0% to $-83M since the same quarter in the previous year.
Based on the above factors, Galapagos NV gets an overall score of 4/5.